Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma

Trial Profile

Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Trabectedin (Primary) ; Dacarbazine
  • Indications Leiomyosarcoma; Liposarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 30 Dec 2016 Planned End Date changed from 1 Feb 2019 to 1 Dec 2018.
    • 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Jun 2015 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top